Orano Med
Varaidzo M. is a Research Associate I at Orano Med since August 2023, with prior experience as an Undergraduate Research Assistant at UNT BioDiscovery Institute from January 2022 to June 2023, where research focused on protein structures and biosynthetic pathways to enhance health across plant, animal, and human domains. Varaidzo M. has practical skills in laboratory protocols involving transformation, DNA extraction, protein expression, purification, and crystallization. Additionally, from January 2023 to May 2023, Varaidzo M. served as a Supplemental Instruction Leader at the University of North Texas, facilitating study sessions in probability, statistics, and Microsoft Excel for statistical analysis. Earlier experience includes a position as a Research Assistant at the Theodore Roosevelt Center in late 2019, where responsibilities involved sorting and digitizing historical documents for scholarly access. Varaidzo M. holds a Bachelor's degree in Biochemistry from the University of North Texas.
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.